NCT04302805View on ClinicalTrials.gov

rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT)

PHASE3CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 27, 2020

Primary Completion Date

April 15, 2024

Study Completion Date

June 15, 2024

Conditions
Kidney Transplantation
Interventions
DRUG

Privigen

Patients randomized to PE/rATG/IVIG group will receive IVIG 0.5g/kg infusions, on 1st, 3rd and 5th postoperative day.

DRUG

Thymoglobulin

All patients will receive 1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg.

OTHER

Plasma Exchange

All patient will undergo Plasma Exchange before transplantation.

Trial Locations (1)

140 21

Institute for Clinical and Experimental Medicine, Prague

All Listed Sponsors
lead

Institute for Clinical and Experimental Medicine

OTHER_GOV

NCT04302805 - rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT) | Biotech Hunter | Biotech Hunter